Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT ID: NCT06132958
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
710 participants
INTERVENTIONAL
2023-12-06
2028-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab tirumotecan
Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Day 1 of each 14-day cycle. Additionally, participants receive diphenhydramine (or equivalent), a Histamine (H2 antagonist) of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
Sacituzumab tirumotecan
4 mg/kg of sacituzumab tirumotecan by IV infusion
Chemotherapy
Participants will receive 60 mg/m\^2 of doxorubicin by IV infusion on Day 1 of each 21-day cycle; or 80 mg/m\^2 of paclitaxel by IV infusion on Days 1, 8, and 15 of each 28-day cycle. Participants who experience either a severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive Nab-paclitaxel.
Doxorubicin
60 mg/m\^2 of doxorubicin by IV Infusion
Paclitaxel
80 mg/m\^2 of paclitaxel by IV infusion
Nab-paclitaxel
100 mg/m\^2 of nab-paclitaxel by IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab tirumotecan
4 mg/kg of sacituzumab tirumotecan by IV infusion
Doxorubicin
60 mg/m\^2 of doxorubicin by IV Infusion
Paclitaxel
80 mg/m\^2 of paclitaxel by IV infusion
Nab-paclitaxel
100 mg/m\^2 of nab-paclitaxel by IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has radiographically evaluable disease, either measurable or nonmeasurable per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR).
* Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.
Exclusion Criteria
* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has had a recurrence of endometrial carcinoma or carcinosarcoma more than \>12 months after completing platinum-based therapy administered in the curative-intent setting without any additional platinum-based therapy received in the recurrent setting. Note: 1) If Immunotherapy-based treatment is administered in the recurrent setting, then platinum rechallenge is not required, regardless of the duration of the platinum-free interval from time of adjuvant therapy 2) For Stage IVb disease, treatment that includes gynecological surgery followed by a platinum-based regimen is NOT considered curative-intent per protocol and does not require platinum rechallenge in the recurrent setting, regardless of the duration of the platinum-free interval
* Has received more than 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma
* Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has received prior treatment with single-agent nonplatinum based chemotherapy in the third-line setting
* Has received prior treatment with a trophoblast cell surface antigen 2 (TROP2)-targeted antibody drug conjugate (ADC) (eg, sacituzumab govitecan)
* Has received prior treatment with a topoisomerase I inhibitor-containing ADC (eg, sacituzumab govitecan or fam-trastuzumab deruxtecan-nxki)
* Has previously received both single-agent paclitaxel and single-agent doxorubicin in any setting for prior treatment of endometrial cancer
* Requires recurrent drainage of effusions (e.g., pleural, ascitic, etc.) within 6 weeks before randomization
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Network for Gynaecological Oncological Trial groups(ENGOT)
UNKNOWN
GOG Foundation
NETWORK
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USA Mitchell Cancer Institute ( Site 4142)
Mobile, Alabama, United States
Alaska Womens Cancer Care ( Site 4122)
Anchorage, Alaska, United States
HonorHealth (HH) ( Site 8000)
Phoenix, Arizona, United States
Arizona Oncology Associates - HOPE ( Site 8002)
Tucson, Arizona, United States
UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4131)
Los Angeles, California, United States
California Pacific Medical Center - Van Ness Campus ( Site 4129)
San Francisco, California, United States
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114)
New Haven, Connecticut, United States
MedStar Washington Hospital Center ( Site 4108)
Washington D.C., District of Columbia, United States
Mount Sinai Cancer Center ( Site 4117)
Miami Beach, Florida, United States
AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113)
Orlando, Florida, United States
Florida Cancer Specialists - East ( Site 7000)
West Palm Beach, Florida, United States
Northside Hospital ( Site 4112)
Atlanta, Georgia, United States
Augusta University ( Site 4116)
Augusta, Georgia, United States
Centricity Research Columbus Cancer Center ( Site 4154)
Columbus, Georgia, United States
NorthShore University HealthSystem - Evanston Hospital ( Site 4110)
Evanston, Illinois, United States
Parkview Research Center at Parkview Regional Medical Center ( Site 4132)
Fort Wayne, Indiana, United States
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 4150)
Edgewood, Kentucky, United States
University Medical Center New Orleans ( Site 4133)
New Orleans, Louisiana, United States
TRIALS 365 ( Site 4105)
Shreveport, Louisiana, United States
University of Massachusetts Memorial Medical Center ( Site 4103)
Worcester, Massachusetts, United States
Washington University School of Medicine-Obstetrics & Gynecology ( Site 4146)
St Louis, Missouri, United States
The Center of Hope ( Site 4109)
Reno, Nevada, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 4118)
Hackensack, New Jersey, United States
Atlantic Health System Morristown Medical Center ( Site 4135)
Morristown, New Jersey, United States
Holy Name Medical Center ( Site 4115)
Teaneck, New Jersey, United States
New York - Presbyterian Brooklyn Methodist Hospital ( Site 4134)
Brooklyn, New York, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 4156)
Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center ( Site 4106)
New York, New York, United States
Icahn School of Medicine at Mount Sinai-Department of Obstetrics, Gynecology, and Reproductive Scie ( Site 4128)
New York, New York, United States
Good Samaritan Hospital Medical Center ( Site 4139)
West Islip, New York, United States
Duke Cancer Institute ( Site 4120)
Durham, North Carolina, United States
Sanford Health Roger Maris Cancer Center ( Site 4158)
Fargo, North Dakota, United States
University of Cincinnati Medical Center ( Site 4136)
Cincinnati, Ohio, United States
Sidney Kimmel Cancer Center - Jefferson Health ( Site 4157)
Philadelphia, Pennsylvania, United States
AHN West Penn Hospital-Gynecologic Oncology ( Site 4111)
Pittsburgh, Pennsylvania, United States
Asplundh Cancer Pavilion ( Site 4107)
Willow Grove, Pennsylvania, United States
Women & Infants Hospital ( Site 4138)
Providence, Rhode Island, United States
Sanford Cancer Center-Gynecologic Oncology ( Site 4121)
Sioux Falls, South Dakota, United States
The West Clinic, PLLC dba West Cancer Center ( Site 4102)
Germantown, Tennessee, United States
Houston Methodist Hospital-Obstetrics and Gynecology ( Site 4130)
Houston, Texas, United States
Texas Oncology - San Antonio ( Site 8005)
San Antonio, Texas, United States
Texas Oncology - Gulf Coast ( Site 8006)
The Woodlands, Texas, United States
Hospital Británico de Buenos Aires-Oncology ( Site 1002)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Argentino de Diagnóstico y Tratamiento (IADT) ( Site 1008)
Buenos Aires, Buenos Aires F.D., Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 1007)
Buenos Aires, Buenos Aires F.D., Argentina
Hospital Aleman-Oncology ( Site 1001)
Buenos Aires, , Argentina
Instituto de Oncología Angel H. Roffo ( Site 1003)
Buenos Aires, , Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1004)
Buenos Aires, , Argentina
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 1006)
La Rioja, , Argentina
GenesisCare North Shore ( Site 1103)
St Leonards, New South Wales, Australia
Blacktown Hospital ( Site 1101)
Sydney, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 1102)
Brisbane, Queensland, Australia
Epworth Freemasons ( Site 1104)
East Melbourne, Victoria, Australia
Frankston Hospital ( Site 1105)
Frankston, Victoria, Australia
Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 1201)
Innsbruck, Tyrol, Austria
Medizinische Universität Wien ( Site 1202)
Vienna, , Austria
AZ Maria Middelares-IKG ( Site 1305)
Ghent, Oost-Vlaanderen, Belgium
UZ Gent-Medical oncology ( Site 1303)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven-Gynecologic Oncology ( Site 1301)
Leuven, Vlaams-Brabant, Belgium
AZ Delta vzw-Oncology ( Site 1302)
Roeselare, West-Vlaanderen, Belgium
CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 1304)
Namur, , Belgium
Hospital São Domingos ( Site 1365)
São Luís, Maranhão, Brazil
Centro Oncologico do Triangulo ( Site 1360)
Uberlândia, Minas Gerais, Brazil
Hospital Moinhos de Vento ( Site 1359)
Porto Alegre, Rio Grande do Sul, Brazil
Instituto Joinvilense de Hematologia e Oncologia ( Site 1353)
Joinville, Santa Catarina, Brazil
Instituto de Ensino e Pesquisa ( Site 1355)
Sorocaba, São Paulo, Brazil
Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 1352)
Rio de Janeiro, , Brazil
Hospital Samaritano De Sao Paulo ( Site 1367)
São Paulo, , Brazil
A. C. Camargo Cancer Center ( Site 1351)
São Paulo, , Brazil
IBCC - Núcleo de Pesquisa e Ensino ( Site 1366)
São Paulo, , Brazil
Arthur J.E. Child Comprehensive Cancer Centre ( Site 1413)
Calgary, Alberta, Canada
Cross Cancer Institute ( Site 1414)
Edmonton, Alberta, Canada
BC Cancer Vancouver ( Site 1415)
Vancouver, British Columbia, Canada
Trillium Health Partners - Credit Valley Hospital ( Site 1410)
Mississauga, Ontario, Canada
CIUSSS- saguenay-Lac-Saint-Jean ( Site 1408)
Chicoutimi, Quebec, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 1405)
Montreal, Quebec, Canada
Centre Hospitalier de l'Université de Montréal ( Site 1403)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 1404)
Montreal, Quebec, Canada
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1505)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 1503)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 1501)
Santiago, Region M. de Santiago, Chile
James Lind Centro de Investigacion del Cancer ( Site 1504)
Temuco, Región de la Araucanía, Chile
Second Affiliated hospital of Anhui Medical University-Oncology ( Site 1635)
Hefei, Anhui, China
Beijing Obstetric and Gynecology Hospital ( Site 1653)
Beijing, Beijing Municipality, China
Fujian Cancer Hospital-Gynecological Oncology Surgery ( Site 1627)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 1613)
Xiamen, Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 1634)
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center ( Site 1604)
Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College ( Site 1642)
Shantou, Guangdong, China
Affiliated Hospital of Guangdong Medical University ( Site 1614)
Zhanjiang, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 1622)
Nanning, Guangxi, China
Hainan General Hospital ( Site 1636)
Haikou, Hainan, China
Harbin Medical University Cancer Hospital-Gynecological Radiotherapy Department ( Site 1652)
Harbin, Heilongjiang, China
Henan Cancer Hospital ( Site 1618)
Zhengzhou, Henan, China
The Second Affiliated Hospital of Zhengzhou University ( Site 1640)
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1621)
Wuhan, Hubei, China
Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 1607)
Wuhan, Hubei, China
Xiangya Hospital Central South University-Gynecology ( Site 1603)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 1623)
Changsha, Hunan, China
Nanjing First Hospital ( Site 1649)
Nanjing, Jiangsu, China
Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 1625)
Nanchang, Jiangxi, China
LinYi Cancer Hospital-Gastrology department ( Site 1630)
Linyi, Shandong, China
Obstetrics & Gynecology Hospital of Fudan University ( Site 1617)
Shanghai, Shanghai Municipality, China
Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 1626)
Shanghai, Shanghai Municipality, China
West China Second University Hospital, Sichuan University ( Site 1602)
Chengdu, Sichuan, China
Sichuan Cancer hospital-Oncology ( Site 1650)
Chengdu, Sichuan, China
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 1648)
Ürümqi, Xinjiang, China
Yunnan Province Cancer Hospital-Gynecology Department ( Site 1641)
Kunming, Yunnan, China
The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 1609)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital-Oncology ( Site 1601)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 1633)
Linhai, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 1615)
Wenzhou, Zhejiang, China
Fakultní Nemocnice Brno-Gynekologicko-porodnicka klinika ( Site 1704)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 1703)
Ostrava, Moravskoslezský kraj, Czechia
Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 1706)
Nový Jiín, Novy Jicin, Czechia
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1702)
Olomouc, Olomoucký kraj, Czechia
Fakultni nemocnice Kralovske Vinohrady ( Site 1707)
Prague, Praha 10, Czechia
Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1705)
Prague, Praha 2, Czechia
Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 1701)
Prague, Praha 8, Czechia
Herlev and Gentofte Hospital-Department of Oncology ( Site 1801)
Copenhagen, Capital Region, Denmark
Rigshospitalet-Dept. of Oncology ( Site 1803)
Copenhagen, Capital Region, Denmark
Aarhus Universitetshospital, Skejby ( Site 1802)
Aarhus, Central Jutland, Denmark
Kuopion Yliopistollinen Sairaala ( Site 1904)
Kuopio, Northern Savonia, Finland
Tampereen yliopistollinen sairaala ( Site 1901)
Tampere, Pirkanmaa, Finland
Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1903)
Turku, Southwest Finland, Finland
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1902)
Helsinki, Uusimaa, Finland
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 2002)
Bordeaux, Aquitaine, France
CENTRE LEON BERARD ( Site 2004)
Lyon Cedex08, Auvergne-Rhône-Alpes, France
ROC37 ( Site 2010)
Chambray-lès-Tours, Centre-Val de Loire, France
Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 2001)
Plérin, Cotes-d Armor, France
CHU Besançon ( Site 2009)
Besançon, Doubs, France
Institut Claudius Regaud ( Site 2006)
Toulouse, Haute-Garonne, France
Centre Oscar Lambret ( Site 2007)
Lille, Hauts-de-France, France
Institut Regional du Cancer Montpellier ( Site 2008)
Montpellier, Herault, France
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 2003)
Rennes, Ille-et-Vilaine, France
Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 2005)
Paris, , France
SLK-Kliniken Heilbronn ( Site 2107)
Heilbronn, Baden-Wurttemberg, Germany
Universitätsmedizin Mannheim-Department of Obstetrics and Gynecology ( Site 2101)
Mannheim, Baden-Wurttemberg, Germany
MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum ( Site 2110)
Ravensburg, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen ( Site 2111)
Tübingen, Baden-Wurttemberg, Germany
Klinikum der Universität München Großhadern-Klinik und Poliklinik für Frauenheilkunde und Geburtshi ( Site 2109)
Munich, Bavaria, Germany
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 2104)
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur ( Site 2103)
Dresden, Saxony, Germany
Charité Campus Virchow-Klinikum ( Site 2102)
Berlin, , Germany
Agios Andreas Hospital Patras ( Site 2201)
Pátrai, Achaia, Greece
Aretaieio Hospital Oncology Unit ( Site 2206)
Athens, Attica, Greece
Metropolitan Hospital-2nd Oncology Dept ( Site 2202)
Athens, Attica, Greece
Hygeia Hospital ( Site 2204)
Marousi, Attica, Greece
Cork University Hospital ( Site 2402)
Cork, , Ireland
Mater Misericordiae University Hospital ( Site 2403)
Dublin, , Ireland
St. James's Hospital-Cancer clinical trials office ( Site 2401)
Dublin, , Ireland
Rambam Health Care Campus-Gyneco-oncology unit ( Site 2502)
Haifa, , Israel
Edith Wolfson Medical Center ( Site 2501)
Holon, , Israel
Shaare Zedek Medical Center ( Site 2503)
Jerusalem, , Israel
Rabin Medical Center ( Site 2505)
Petah Tikva, , Israel
Sheba Medical Center ( Site 2504)
Ramat Gan, , Israel
Sourasky Medical Center ( Site 2506)
Tel Aviv, , Israel
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-SSD Oncologia medica Addarii ( Site 2603)
Bologna, Emilia-Romagna, Italy
CRO-IRCCS ( Site 2609)
Aviano, Friuli Venezia Giulia, Italy
AOU Policlinico Umberto I ( Site 2606)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 2605)
Milan, Lombardy, Italy
Istituto Europeo di Oncologia IRCCS ( Site 2607)
Milan, Lombardy, Italy
Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 2610)
Rozzano, Milano, Italy
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'O-Day Hospital Oncologico Multidisciplin ( Site 2613)
Candiolo, Torino, Italy
Instituto Tumori Giovanni Paolo II-ONCOLOGIA MEDICA ( Site 2604)
Bari, , Italy
Azienda Ospedaliera Spedali Civili di Brescia-Obstetrics anf gynecology ( Site 2611)
Brescia, , Italy
Humanitas San Pio X Hospital ( Site 2614)
Milan, , Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 2602)
Napoli, , Italy
Arcispedale Santa Maria Nuova ( Site 2612)
Reggio Emilia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2601)
Roma, , Italy
Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 2608)
Torino, , Italy
Aichi Cancer Center ( Site 2714)
Nagoya, Aichi-ken, Japan
National Hospital Organization Shikoku Cancer Center ( Site 2705)
Matsuyama, Ehime, Japan
Ehime University Hospital ( Site 2709)
Tōon, Ehime, Japan
Kurume University Hospital ( Site 2703)
Kurume, Fukuoka, Japan
Gunma Prefectural Cancer Center ( Site 2708)
Otashi, Gunma, Japan
Hokkaido University Hospital ( Site 2707)
Sapporo, Hokkaido, Japan
University of Tsukuba Hospital ( Site 2713)
Tsukuba, Ibaraki, Japan
Iwate Medical University Hospital ( Site 2712)
Shiwa-gun, Iwate, Japan
Niigata Cancer Center Hospital ( Site 2701)
Niigata, Niigata, Japan
Saitama Medical University International Medical Center ( Site 2710)
Hidaka, Saitama, Japan
Shizuoka Cancer Center ( Site 2716)
Sunto-gun,, Shizuoka, Japan
National Cancer Center Hospital ( Site 2715)
Chuo-ku, Tokyo, Japan
Cancer Institute Hospital of JFCR ( Site 2706)
Koto, Tokyo, Japan
Showa Medical University Hospital ( Site 2719)
Shinagawa, Tokyo, Japan
Keio University Hospital ( Site 2702)
Shinjuku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center ( Site 2711)
Fukuoka, , Japan
Kagoshima City Hospital ( Site 2717)
Kagoshima, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 2718)
Osaka, , Japan
Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 2803)
Kuala Lumpur, , Malaysia
University Malaya Medical Centre ( Site 2801)
Kuala Lumpur, , Malaysia
COI Centro Oncologico Internacional S.A.P.I. de C.V. ( Site 2902)
Coyoacán, Mexico City, Mexico
Higiea Oncologia ( Site 2905)
Mexico City, Mexico City, Mexico
Oncare - Unidad Valle ( Site 2906)
San Pedro Garza García, Nuevo León, Mexico
CENTRO MEDICO ZAMBRANO HELLION-Centro de Cáncer de Mama ( Site 2901)
San Pedro Garza García, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 2907)
Oaxaca City, Oaxaca, Mexico
Radboudumc-Medical Oncology ( Site 3003)
Nijmegen, Gelderland, Netherlands
Amsterdam UMC - locatie VUmc ( Site 3004)
Amsterdam, North Holland, Netherlands
Leids Universitair Medisch Centrum-Medical Oncology ( Site 3002)
Leiden, South Holland, Netherlands
Stavanger Universitetssykehus ( Site 3103)
Stavanger, Rogaland, Norway
Universitetssykehuset Nord-Norge HF ( Site 3101)
Tromsø, Troms, Norway
Sorlandet Sykehus Kristiansand ( Site 3104)
Kristiansand, Vest-Agder, Norway
Oslo universitetssykehus, Radiumhospitalet ( Site 3102)
Oslo, , Norway
Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie-Oddział Radioterapii i Onkologii Ginek ( Site 3202)
Poznan, Greater Poland Voivodeship, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3201)
Siedlce, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Site 3203)
Warsaw, Masovian Voivodeship, Poland
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 3204)
Bialystok, Podlaskie Voivodeship, Poland
Ad-Vance Medical Research-Research ( Site 3302)
Ponce, , Puerto Rico
Pan American Center for Oncology Trials - Ciudadela ( Site 3301)
San Juan, , Puerto Rico
UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 3304)
San Juan, , Puerto Rico
National Cancer Centre Singapore-Medical Oncology ( Site 3401)
Singapore, Central Singapore, Singapore
Seoul National University Bundang Hospital-Obstetrics and Gynecology ( Site 3505)
Seongnam, Kyonggi-do, South Korea
Seoul National University Hospital ( Site 3502)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 3503)
Seoul, , South Korea
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 3501)
Seoul, , South Korea
Samsung Medical Center ( Site 3504)
Seoul, , South Korea
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 3608)
L'Hospitalet de Llobregat, Barcelona, Spain
Institut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 3606)
Girona, Gerona, Spain
Clinica Universidad de Navarra ( Site 3603)
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 3607)
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario La Paz-Oncología Médica ( Site 3604)
Madrid, Madrid, Comunidad de, Spain
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 3605)
Valencia, Valenciana, Comunitat, Spain
HOSPITAL CLINICO DE VALENCIA ( Site 3609)
Valencia, Valenciana, Comunitat, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 3602)
Barcelona, , Spain
Hospital Universitario Reina Sofia-Oncologia Medica ( Site 3601)
Córdoba, , Spain
Skånes Universitetssjukhus Lund ( Site 3702)
Lund, Skåne County, Sweden
Karolinska Universitetssjukhuset Solna ( Site 3701)
Stockholm, Stockholm County, Sweden
University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 3808)
Basel, Canton of Basel-City, Switzerland
Ospedale Regionale Bellinzona e Valli ( Site 3802)
Bellinzona, Canton Ticino, Switzerland
Kantonsspital Graubünden-Medizin ( Site 3803)
Chur, Kanton Graubünden, Switzerland
Inselspital Bern-Oncology ( Site 3801)
Bern, , Switzerland
University Hospitals Sussex NHS Foundation Trust ( Site 4006)
East Sussex, Brighton And Hove, United Kingdom
Royal Derby Hospital ( Site 4007)
Derby, Derbyshire, United Kingdom
ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre ( Site 4002)
London, England, United Kingdom
The Royal Cornwall Hospital ( Site 4009)
Truro, England, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 4004)
London, London, City of, United Kingdom
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 4008)
London, London, City of, United Kingdom
Hammersmith Hospital ( Site 4001)
London, London, City of, United Kingdom
The Beatson West of Scotland Cancer Centre ( Site 4005)
Glasgow, Scotland, United Kingdom
Royal Marsden Hospital (Sutton)-Gynaecology Unit ( Site 4010)
London, Sutton, United Kingdom
The Christie NHS Foundation Trust-Medical Oncology ( Site 4003)
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2870-005
Identifier Type: -
Identifier Source: org_study_id
2023-504816-14-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1288-7581
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2031240041
Identifier Type: REGISTRY
Identifier Source: secondary_id